DOPA Decarboxylase Antibodies

DOPA decarboxylase (DDC) is a key enzyme in dopamine synthesis and has recently gained attention as a fluid biomarker for Lewy body disorders. Cerebrospinal fluid (CSF) DDC levels are elevated in Parkinson’s disease (PD) and dementia with Lewy bodies, and this increase is already detectable in prodromal and de novo PD, where CSF, but not plasma, DDC is elevated, highlighting its potential as an early‑stage biomarker 1. In contrast, plasma DDC elevations are largely driven by dopaminergic treatment, not disease pathology, indicating that peripheral DDC measurements may be confounded by medication effects2.

The ADx411 and ADx412 monoclonal antibodies against DDC allow the development of immunoassays for quantifying this biomarker in CSF.

Contact sales for information
ADx411 - mAb mouse anti DDC

Product number 90583

1 mg
ADx412 - mAb mouse anti DDC

Product number 90584

1 mg

Click here to navigate

  • Contact sales for information
  • Details
  • Insights
  • Product inquiry
  • Related products
  • Webinars

Veuillez confirmer que vous êtes un professionnel de la santé

Le contenu de ce site web est en partie réservé aux professionnels de santé qui sont directement impliqués dans la fourniture de services de soins de santé aux patients. Si vous êtes un professionnel de santé et que vous disposez de tous les droits d'accès, veuillez confirmer en cliquant sur le bouton 'oui'.

Choose your country or region

Once you have made this selection we will show you only the content that is relevant for your country. You can change this setting any time by clicking on the flag in the top toolbar of our website and choosing another country.
The content of this website is in part restricted to healthcare professionals who are directly involved in the provision of healthcare services to patients. If you are a health professional and you have full access rights, please check this box and confirm below.